دورية أكاديمية
The Prognostic, Diagnostic, and Therapeutic Potential of TRAIL Signalling in Cardiovascular Diseases.
العنوان: | The Prognostic, Diagnostic, and Therapeutic Potential of TRAIL Signalling in Cardiovascular Diseases. |
---|---|
المؤلفون: | Kelland E; Heart Research Institute, The University of Sydney, Sydney 2042, Australia., Patil MS; Heart Research Institute, The University of Sydney, Sydney 2042, Australia., Patel S; Heart Research Institute, The University of Sydney, Sydney 2042, Australia.; Royal Prince Alfred Hospital, Sydney 2006, Australia., Cartland SP; Heart Research Institute, The University of Sydney, Sydney 2042, Australia., Kavurma MM; Heart Research Institute, The University of Sydney, Sydney 2042, Australia. |
المصدر: | International journal of molecular sciences [Int J Mol Sci] 2023 Apr 04; Vol. 24 (7). Date of Electronic Publication: 2023 Apr 04. |
نوع المنشور: | Journal Article; Review |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, [2000- |
مواضيع طبية MeSH: | Cardiovascular Diseases*/diagnosis , Cardiovascular Diseases*/therapy , Cardiovascular Diseases*/complications , Atherosclerosis*/pathology , Diabetes Mellitus*, Humans ; TNF-Related Apoptosis-Inducing Ligand/therapeutic use ; Prognosis ; Apoptosis |
مستخلص: | TNF-related apoptosis-inducing ligand (TRAIL) was originally discovered, almost 20 years ago, for its ability to kill cancer cells. More recent evidence has described pleiotropic functions, particularly in the cardiovascular system. There is potential for TRAIL concentrations in the circulation to act as prognostic and/or diagnostic factors for cardiovascular diseases (CVD). Pre-clinical studies also describe the therapeutic capacity for TRAIL signals, particularly in the context of atherosclerotic disease and diseases of the myocardium. Because diabetes mellitus significantly contributes to the progression and pathogenesis of CVDs, in this review we highlight recent evidence for the prognostic, diagnostic, and therapeutic potential of TRAIL signals in CVDs, and where relevant, the impact of diabetes mellitus. A greater understanding of how TRAIL signals regulate cardiovascular protection and pathology may offer new diagnostic and therapeutic avenues for patients suffering from CVDs. |
References: | J Cell Commun Signal. 2017 Sep;11(3):219-226. (PMID: 28101818) Clin Res Cardiol. 2021 Jul;110(7):1006-1019. (PMID: 32789678) Int J Cardiol. 2013 Sep 30;168(2):1251-7. (PMID: 23218577) J Mol Endocrinol. 2021 May 11;66(4):325-338. (PMID: 33875613) Diabetologia. 2011 Dec;54(12):3157-67. (PMID: 21965021) Stroke. 2019 Aug;50(8):1989-1996. (PMID: 31272321) J Histochem Cytochem. 2004 Jun;52(6):821-31. (PMID: 15150291) Medicine (Baltimore). 2014 Dec;93(29):e154. (PMID: 25546658) J Am Heart Assoc. 2015 Nov 16;4(11):. (PMID: 26572549) Eur Heart J. 2009 Apr;30(7):789-96. (PMID: 19196721) Front Mol Biosci. 2021 Mar 10;8:628332. (PMID: 33791337) Biomed Res Int. 2015;2015:259843. (PMID: 26504794) Clin Endocrinol (Oxf). 2014 Feb;80(2):228-34. (PMID: 23931066) Eur J Prev Cardiol. 2017 Oct;24(15):1576-1583. (PMID: 28762762) Science. 1997 Aug 8;277(5327):815-8. (PMID: 9242610) Adv Med Sci. 2016 Sep;61(2):269-275. (PMID: 27128817) Thromb Res. 2010 Dec;126(6):e423-7. (PMID: 20932553) Med Sci Monit. 2013 Aug 29;19:712-5. (PMID: 23986130) J Biol Chem. 2008 Mar 21;283(12):7754-62. (PMID: 18178561) Cell Death Dis. 2012 Jun 14;3:e321. (PMID: 22695614) J Biol Chem. 1996 May 31;271(22):12687-90. (PMID: 8663110) Diabetes Res Clin Pract. 2012 Jun;96(3):e84-6. (PMID: 22446096) J Intern Med. 2010 Apr;267(4):410-7. (PMID: 19895657) Thromb Res. 2010 Apr;125(4):322-5. (PMID: 20034655) Circ Res. 2010 Apr 2;106(6):1061-71. (PMID: 20150555) Free Radic Biol Med. 2018 Oct;126:341-349. (PMID: 30165101) Atherosclerosis. 2011 Apr;215(2):348-54. (PMID: 21324463) Cardiology. 2013;124(3):190-8. (PMID: 23486075) Vasc Health Risk Manag. 2007;3(6):853-76. (PMID: 18200806) Curr Opin Lipidol. 2017 Apr;28(2):91-98. (PMID: 28134664) Circulation. 2005 May 17;111(19):2461-8. (PMID: 15883214) J Clin Med. 2022 May 02;11(9):. (PMID: 35566677) Eur Heart J. 2020 Jun 14;41(23):2153-2163. (PMID: 31504417) Atherosclerosis. 2011 Apr;215(2):452-8. (PMID: 21122855) Int J Mol Sci. 2022 Mar 17;23(6):. (PMID: 35328646) Circulation. 2021 May 25;143(21):e984-e1010. (PMID: 33882682) J Immunol. 2003 Aug 1;171(3):1526-33. (PMID: 12874246) Atherosclerosis. 2014 Oct;236(2):230-6. (PMID: 25104079) Transl Stroke Res. 2021 Dec;12(6):946-957. (PMID: 34195928) Stroke. 2022 Sep;53(9):2847-2858. (PMID: 35686557) Invest New Drugs. 2012 Jun;30(3):1257-60. (PMID: 21197620) PLoS One. 2015 Sep 03;10(9):e0136414. (PMID: 26334877) J Am Coll Cardiol. 2019 Aug 27;74(8):1107-1115. (PMID: 31439220) Sci Transl Med. 2020 Apr 22;12(540):. (PMID: 32321866) Atherosclerosis. 2014 Dec;237(2):718-24. (PMID: 25463111) Am J Cardiol. 2012 Feb 15;109(4):515-20. (PMID: 22100028) Sci Rep. 2017 May 15;7(1):1898. (PMID: 28507343) Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1420-5. (PMID: 15845913) PLoS Med. 2021 Jan 13;18(1):e1003513. (PMID: 33439866) PLoS One. 2014 Jan 22;9(1):e87059. (PMID: 24466325) J Am Coll Cardiol. 2004 Nov 16;44(10):1970-6. (PMID: 15542278) Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):857-63. (PMID: 16424351) PLoS One. 2013 Sep 05;8(9):e74211. (PMID: 24040204) Diabetes Res Clin Pract. 2011 Mar;91(3):316-20. (PMID: 21227528) Physiol Rep. 2020 Oct;8(20):e14612. (PMID: 33080110) J Cell Biochem. 2012 Aug;113(8):2597-606. (PMID: 22415975) J Surg Res. 2007 Oct;142(2):227-32. (PMID: 17706969) Cell Death Differ. 2012 Dec;19(12):2003-14. (PMID: 22814620) Biomedica. 2022 May 01;42(Sp. 1):55-63. (PMID: 35866730) Angiology. 2010 Nov;61(8):756-62. (PMID: 20498140) Respir Med. 2018 Dec;145:21-27. (PMID: 30509711) Cardiology. 2010;116(4):302-7. (PMID: 20881386) J Stroke Cerebrovasc Dis. 2019 May;28(5):1160-1167. (PMID: 30658955) Eur Heart J. 2019 Apr 21;40(16):1268-1276. (PMID: 30615112) Cardiovasc Diabetol. 2018 Jun 8;17(1):83. (PMID: 29884191) Eur J Heart Fail. 2009 Sep;11(9):825-31. (PMID: 19654138) J Cell Physiol. 2007 Jul;212(1):89-95. (PMID: 17352408) Am Heart J. 2010 Aug;160(2):286-93. (PMID: 20691834) Circulation. 2006 Oct 3;114(14):1522-30. (PMID: 17000905) J Am Coll Cardiol. 2003 Mar 5;41(5):753-60. (PMID: 12628718) J Clin Med. 2021 Mar 18;10(6):. (PMID: 33803523) Front Neurol. 2018 Mar 05;9:102. (PMID: 29556210) Life Sci. 2005 May 27;77(2):160-74. (PMID: 15862601) J Mol Cell Cardiol. 2019 Nov;136:1-14. (PMID: 31473246) PLoS One. 2013;8(2):e53860. (PMID: 23441146) Int J Cardiol. 2013 Jul 1;166(3):702-8. (PMID: 22178057) iScience. 2019 Feb 22;12:41-52. (PMID: 30665196) Biochem Biophys Res Commun. 2005 Dec 30;338(4):1745-50. (PMID: 16288714) Circ Cardiovasc Genet. 2017 Feb;10(1):. (PMID: 28100627) J Nephrol. 2019 Feb;32(1):111-119. (PMID: 30499038) Sci Rep. 2017 Mar 16;7:44735. (PMID: 28300219) Cancer Res. 2008 Aug 1;68(15):6035-7. (PMID: 18676822) Mediators Inflamm. 2016;2016:6529728. (PMID: 28070143) Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2117-24. (PMID: 16840715) Int J Mol Sci. 2016 Dec 02;17(12):. (PMID: 27918462) Atherosclerosis. 2015 May;240(1):228-33. (PMID: 25813908) Neoplasia. 2004 Jul-Aug;6(4):364-73. (PMID: 15256058) Transl Stroke Res. 2020 Aug;11(4):601-614. (PMID: 31776837) J Intern Med. 2020 Nov;288(5):581-592. (PMID: 32638487) J Thromb Haemost. 2011 Apr;9(4):638-44. (PMID: 21284802) Atherosclerosis. 2020 May;301:8-14. (PMID: 32289619) Clin Biochem. 2013 Aug;46(12):1020-1025. (PMID: 23481489) Immunity. 1995 Dec;3(6):673-82. (PMID: 8777713) Circulation. 2003 May 6;107(17):2250-6. (PMID: 12668516) PLoS One. 2014 Mar 25;9(3):e92952. (PMID: 24667560) J Diabetes. 2016 Jul;8(4):568-78. (PMID: 26333348) Biochem Biophys Res Commun. 2010 Jan 1;391(1):936-41. (PMID: 19962958) J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. (PMID: 33309175) Eur J Heart Fail. 2018 Jan;20(1):55-62. (PMID: 28967680) FASEB J. 2020 Jul;34(7):9547-9562. (PMID: 32501591) Medicine (Baltimore). 2019 Mar;98(10):e14489. (PMID: 30855435) Diabetes. 2003 Sep;52(9):2274-8. (PMID: 12941766) Heart Vessels. 2023 Mar;38(3):448-458. (PMID: 36344842) |
معلومات مُعتمدة: | 1188218 National Health and Medical Research Council; NA Australian Government Research Training Program; NA Heart Research Institute New Zealand Pathway Program |
فهرسة مساهمة: | Keywords: TRAIL; atherosclerosis; clinical and pre-clinical studies; diabetes; diagnostic and therapeutic potential; heart failure |
المشرفين على المادة: | 0 (TNF-Related Apoptosis-Inducing Ligand) |
تواريخ الأحداث: | Date Created: 20230413 Date Completed: 20230414 Latest Revision: 20230415 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC10095395 |
DOI: | 10.3390/ijms24076725 |
PMID: | 37047698 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1422-0067 |
---|---|
DOI: | 10.3390/ijms24076725 |